



NDA 050441/S-090
NDA 050639/S-044

SUPPLEMENT APPROVALS

Pfizer, Inc.
Attention: Mikhail Abarshalin
Director, Pfizer Global Sciences
66 Hudson Boulevard, East
York, NY 10001

Dear Mikhail Abarshalin:

Please refer to your supplemental new drug applications (sNDAs) dated and received July 18, 2025, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for the following:

- **NDA 050441:** Cleocin Phosphate (clindamycin injection) USP, Sterile Solution, 150 mg/mL
- **NDA 050639:** Cleocin Phosphate (clindamycin injection) 5% dextrose, 300 mg/50 mL, 600 mg/50 mL and 900 mg/50 mL

These “Changes Being Effected” supplemental new drug applications provide for revisions to the **ADVERSE REACTIONS** Section of the prescribing information to include the terms cutaneous vasculitis and symmetrical drug-related intertriginous and flexural exanthema (SDRIFE).

APPROVAL & LABELING

We have completed our review of these applications and they are approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

LABELING

Submit final printed labeling (FPL), as soon as they are available, but no more than 30 days after they are printed. The FPL must be identical to the enclosed labeling (text for the package insert) submitted on July 18, 2025, and must be in the “Drug Facts” format (21 CFR 201.66), where applicable.

The FPL should be submitted electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*.¹ For administrative purposes, designate this submission “**Final Printed Labeling for approved supplemental NDAs 050441/S-090 and 050639/S-044.**” Approval of these submissions by FDA is not required before the labeling is used.

DRUG REGISTRATION AND LISTING

All drug establishment registration and drug listing information is to be submitted to FDA electronically, via the FDA automated system for processing structured product labeling (SPL) files (eLIST). At the time that you submit your final printed labeling (FPL), the content of labeling (Drug Facts) should be submitted in SPL format as described at FDA.gov.² Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*. In addition, representative container or carton labeling, whichever includes Drug Facts, (where differences exist only in the quantity of contents statement) should be submitted as a JPG file.

PATENT LISTING REQUIREMENTS

Pursuant to 21 CFR 314.53(d)(2) and 314.70(f), certain changes to an approved NDA submitted in a supplement require you to submit patent information for listing in the Orange Book upon approval of the supplement. You must submit the patent information required by 21 CFR 314.53(d)(2)(i)(A) through (C) and 314.53(d)(2)(ii)(A) and (C), as applicable, to FDA on Form FDA 3542 within 30 days after the date of approval of the supplement for the patent information to be timely filed (see 21 CFR 314.53(c)(2)(ii)). You also must ensure that any changes to your approved NDA that require the submission of a request to remove patent information from the Orange Book are submitted to FDA at the time of approval of the supplement pursuant to 21 CFR 314.53(d)(2)(ii)(B) and 314.53(f)(2)(iv).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

¹ We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

² <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

NDA 050441/S-090

NDA 050639/S-044

Page 3

If you have any questions, call J. Christopher Davi, MS, Senior Regulatory Project Manager, at (301) 796-0702.

Sincerely,

{See appended electronic signature page}

Dmitri Iarikov, MD, PhD
Deputy Director
Division of Anti-Infectives
Office of Infectious Diseases
Office of New Drugs
Center for Drug Evaluation and Research

ENCLOSURE: Package Insert

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

DMITRI IARIKOV
02/12/2026 01:31:06 PM